Modern medicine has been shaken by the surge of psychedelic science that proposes a new approach to mitigate mental disorders, such as depression and post-traumatic stress disorder. Clinical trials to investigate whether psychedelic substances can treat psychiatric conditions are now underway, yet less discussion gravitates around their use in neurological disorders due to brain injury. One...
MDMA, commonly known as ecstasy or molly, is a synthetic psychoactive drug with a complex history. It produces feelings of increased empathy, emotional connection, and heightened sensory perception. While recreational use of MDMA has been prevalent, recent research suggests significant therapeutic potential in treating mental health conditions like post-traumatic stress disorder (PTSD). This...
Editorial on the Research Topic Down the rabbit hole -the psychological and neural mechanisms of psychedelic compounds and their use in treating mental health and medical conditions Psychedelic substances have demonstrated promising therapeutic effects across a wide range of mental health conditions including depression (1-13) anxiety disorders including generalized anxiety (14-16) and social...
Ketamine is a well-known and widely available general anesthetic from the 1960s that, in sub-anesthetic doses, has been adopted in a limited manner for the treatment of acute suicidality and treatment-resistant depression. Its short onset time and short duration of action make it feasible for use at outpatient clinics. In the US, it has a long history of off-label use and was officially...
PsychiatriaJune 5, 2024Anna Stankiewicz, Jan Szewczyk, Julia Truszkowska et al.1 citation
Drug therapies for many psychiatric conditions do not meet patients’ expectations. New agents are being sought to treat depression and anxiety disorders, among others. Scientific interest in psychoactive substances has increased over the past few decades. Recent studies provide evidence that psychedelics may find use in the treatment of a range of mental disorders. This paper describes new...
Background Numerous clinical trials have supported psychedelic-assisted therapy (PAT) as a treatment for psychiatric disorders such as depression, anxiety, post-traumatic stress, and substance use. While empirical evidence indicates PAT’s benefits, the perspectives of mental health practitioners on this topic remain unclear.Methods This quantitative study attempted to capture psychoanalyst...
AbstractPurpose of ReviewOn 1 July 2023, the Therapeutic Goods Administration approved 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy for the treatment of post‐traumatic stress disorder (PTSD). Accordingly, the purpose of this review is to provide an overview of MDMA and what pharmacists should know as this treatment emerges.Sources of InformationEMBASE, MEDLINE, and CINAHL...
This essay discusses the potential clinical use of 3,4methylenedioxymethamphetamine (MDMA) with patients diagnosed with Post Traumatic Stress Disorder (PTSD). We present a brief history of the use of consciousness-altering substances from ancient times to the present as well as recent research on psychedelic assisted psychotherapy (PAP). Double blind investigation in which some of the...
Recent research into psychedelics has found them to be an effective treatment for disorders related to depression, anxiety, and post traumatic stress disorder. Mystical experiences have proven to mediate the therapeutic effects for outcomes; however, Spanish measures have not been studied thoroughly. In this study we explored the psychometric properties of the Mystical Experience Questionnaire...